Company Filing History:
2 out of 4 
1 out of 15,502 
Years Active: 2011-2014
Title: Richard Bonnichsen: Innovator in Monoclonal Antibody Research
Introduction
Richard Bonnichsen is a notable inventor based in Mahe, GB. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. With a total of 2 patents, his work focuses on innovative solutions for treating diseases, especially cancer.
Latest Patents
Bonnichsen's latest patents include the YKL-40 monoclonal antibody. This invention relates to monoclonal anti-human YKL-antibodies that can modulate biological processes where YKL-40 plays a crucial role. The antibodies are designed to inhibit the growth and induce apoptosis of cells, particularly cancer cells. Furthermore, the invention encompasses pharmaceutical compositions that utilize these antibodies for treating diseases where inhibiting cell growth and inducing cell death are essential for successful treatment. The antibodies work by binding to a specific epitope on YKL-40, effectively inhibiting its biological function in these processes.
Career Highlights
Throughout his career, Richard Bonnichsen has worked with various organizations, including Bio-y A/S and the University of California. His experience in these institutions has allowed him to advance his research and contribute to the scientific community.
Collaborations
Bonnichsen has collaborated with notable individuals in his field, including Paul A. Price. These partnerships have further enhanced his research and development efforts.
Conclusion
Richard Bonnichsen's innovative work in monoclonal antibody research has the potential to significantly impact cancer treatment. His patents reflect a commitment to advancing medical science and improving patient outcomes.